Custom Healthcare Group expands product development services
Custom Development Solutions division is in the process of setting up jv with Brighton University
Custom Healthcare Group (CHG) has expanded its current product development services.
The Hove, UK-based contract manufacturing company currently specialises in the development, manufacture, packing, testing and release of oral solid dosage forms for clinical trials and release to market.
CHG is a small, privately owned business, which has developed its customer base in the UK over the past 32 years by specialising in smaller volume and niche generic, branded prescription and OTC medicines.
Although already an established UK Contract Development Manufacturing Company (CDMO), the recruitment of Dr Michael Crothers to spearhead the newly formed Custom Development Solutions (CDS) team allows the company to provide services to develop more complex and technically challenging generic and branded products.
CDS is in the process of setting up a joint venture with Brighton University to broaden the range of analytical and product development services at its disposal. Dosage forms offered extend beyond the core strengths of solid dose into semi solids, solutions, etc.
Through its in-house expertise, CDS can offer a fully integrated and bespoke CMC package and provides a ‘one-stop-shop’ for product development and commercial supply.
The firm’s modular approach to development includes:
- Analytical method development and validation
- Bespoke and generic formulation development and optimisation
- ICH stability programmes
- Manufacture of Investigational Medicinal Products for clinical trials
- Manufacturing process development, scale-up and validation
- Commercial supply
Custom Healthcare Group’s chief executive Nigel Richardson said: ‘The future of UK manufacturing relies on innovation and technical specialisation. At Custom we have recognised the need to offer new product ideas for our customers to benefit from. By inviting Dr Crothers to join us at Custom we are committing to this added value service to ensure that our customers are well placed to meet the challenges of the UK generic and branded prescription market.
’There are of course significant opportunities in niche and specialist medicines in the UK as well as within the EU. It is our aim to assist and support our customers’ new product plans and to access both the UK and EU opportunities by offering an ‘under-one-roof’ solution to bring products to market together. This is a very exciting time for our business and a great opportunity for our customers to access this new service offering.’
